LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

ClinicalTrials.gov ID: NCT00859222

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00859222. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.

Study identification

NCT ID: NCT00859222
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Patrick Y. Wen, MD; Other
Enrollment: 51 participants

Conditions and interventions

Conditions

Malignant Glioma

Interventions

LBH589 Drug
bevacizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2009 (Type not available)
Primary completion: Sep 2013 (Actual)
Completion: Dec 2015 (Actual)
Last update posted: Mar 14, 2017

2009 – 2015

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Northwestern University	Chicago	Illinois	60611	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Beth-Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
University of Virginia, Department of Neurology	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00859222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 14, 2017 · Synced Nov 14, 2026